Abstract library

8 results for "diet".
#39 Specialist dietetic input and nutritional outcomes in Neuroendocrine Tumour Patients
Introduction: Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that are complex to manage and require a multidisciplinary approach. The most common primary sites are the small intestine and pancreas. The disease itself, as well as sequelae from surgery and medical therapy, can have a negative impact on patients’ nutritional status. Weight loss is known to be a poor prognostic indicator.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MRS CALEY L SCHNAID
Authors: Schnaid C, Khan M, Davies P, Jamieson A, ...
#1884 Towards Optimal Personalized Diet and Vitamin Supplementation in NET Patients; A Feasibility Study
Introduction: Patients with a neuroendocrine tumor (NET) often have gastro-intestinal complaints due to somatostatin analogue (SSA), tumor mass, secretion of neuroendocrine amines or treatment. This can lead to impaired absorption of critical food components such as vitamins. Serotonin producing NET patients may also have low plasma tryptophan.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: drs Ld de Hosson
#2178 Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumor: Preliminary Baseline Characteristics from the Nutrition in NETs Study
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP NET) cause various symptoms impacting on nutritional status and diet. Published data indicates up to 25% of GEP NET patients are malnourished, and dietary change is prevalent. Further research is required to guide nutrition recommendations.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Erin Kennedy
Authors: Kennedy E, Kiss N, Michael M, Gough K, ...
#96 Expression of components of the mTOR pathway in gastroenteropancreatic neuroendocrine tumors
Introduction: Recently, the mammalian target of rapamycin (mTOR) inhibitors have entered late phase clinical trials in a broad variety of solid human malignancies, including neuroendocrine tumors (NETs). Since these drugs will certainly be used as routine therapeutics in the near future, it is surprising that information on the exact expression patterns of mTOR and its downstream target 4EBP1 in NETs is still lacking.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Atsuko Kasajima
#596 Is Deep Enucleation of Small Pancreatic Tumors Justified?
Introduction: Small, potentially benign pancreatic tumors located ≥3mm distant from the main pancreatic duct (MPD) are considered good candidates for enucleation.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Kristin Dietzel
#256 Evaluation of the Association Between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors
Introduction: Bone mineral density (BMD) and fractures are influenced by diet, activity, drugs and hormones. Recent studies highlight an inverse relationship between serotonin and BMD.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Maralyn R Druce
#1062 United Kingdom NET Patient Survey Quality of Life Results
Introduction: QoL is of paramount importance in patients diagnosed with cancer, this is especially true in patients with NETs since the median survival from diagnosis is 7 years.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Raj Srirajaskanthan
Keywords: Quality of life, NET
#1231 Neuroendocrine Tumor (NET) Patient (pt) Experience and Disease Burden: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Global data on impact of NETs on pts’ lives, including differences by disease location, are poorly described. We present global data on pt experience and disease burden by NET type.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Philippe Ruszniewski
Keywords: Symptom burden
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.